WO2006011491A1 - Plasmide vecteur, animal transgénique, procédé de recherche par criblage d'un médicament et médicament - Google Patents

Plasmide vecteur, animal transgénique, procédé de recherche par criblage d'un médicament et médicament Download PDF

Info

Publication number
WO2006011491A1
WO2006011491A1 PCT/JP2005/013667 JP2005013667W WO2006011491A1 WO 2006011491 A1 WO2006011491 A1 WO 2006011491A1 JP 2005013667 W JP2005013667 W JP 2005013667W WO 2006011491 A1 WO2006011491 A1 WO 2006011491A1
Authority
WO
WIPO (PCT)
Prior art keywords
adiponectin
gene
promoter
plasmid vector
mouse
Prior art date
Application number
PCT/JP2005/013667
Other languages
English (en)
Japanese (ja)
Inventor
Shuichi Otabe
Kentaro Yamada
Original Assignee
Kurume University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kurume University filed Critical Kurume University
Publication of WO2006011491A1 publication Critical patent/WO2006011491A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Definitions

  • the present invention relates to a vector that can be used as a model animal that can be used as a disease state model or a disease prevention constitution model, a vector that can produce a large amount of a target substance at a specific site, and the vector And screening methods for drugs such as anti-obesity drugs such as hyperadiponectin, adipose tissue and adipocyte growth inhibitors, weight gain inhibitors, life-prolonging drugs, etc.
  • the present invention relates to a preventive or therapeutic agent for an increase in fat mass such as an increase in fat cells and Z or weight gain caused by sucrose diet intake.
  • Obesity / diabetes / hyperlipidemia / hypertension is caused by visceral fat hypertrophy / accumulation, etc., and is a disease that is a cause of shortening of life. These include intake of high-calorie diet and lack of exercise. It is a type of lifestyle-related disease caused by complicated involvement of environmental factors, and there is a strong need for treatment methods.
  • adipocyte force-in a site force-in specifically expressed in adipocytes.
  • adiponectin which has 244 amino acid strength
  • Abundant force in normal human blood is lacking in patients with obesity and type 2 diabetes, and its deficiency causes insulin resistance, causing not only obesity and type 2 diabetes but also arteriosclerosis It has become clear that this is also the cause.
  • Patent Document 1 Japanese Patent Laid-Open No. 2003-339272
  • the present inventors use a transgenic animal that expresses adiponectin in a larger amount than usual in order to examine whether adiponectin is capable of preventing weight gain due to, for example, ingestion of high-calorie food or the like. Was considered suitable.
  • adiponectin is a substance that exists in a large amount in the blood of normal animals.
  • the expression level in the cell has reached the limit level required in the living body, so that the high adiponectin expression state exceeding the normal level is maintained for a long period of time, and the sustained high adiponectin state is maintained. It was thought that it was almost impossible to search for substances that behave.
  • the present invention It is those that Tsu, it is an object of the present invention, a large amount of issued adiponectin in the liver Provided vectors, transgenic animals using such vectors, screening methods for anti-adiponectinemia or anti-obesity drugs, fat accumulation suppression and Z or weight gain suppression due to increased adipocytes, etc. There is.
  • a plasmid vector containing a liver-specific expression promoter and adiponectin gene is provided.
  • SAP Human serum amyloid P component
  • adiponectin is human adiponectin.
  • a plasmid vector containing a liver-specific expression promoter and a target gene (Sixth invention)
  • a transgeneic rodent animal into which the promoter and adiponectin gene described above are introduced is introduced.
  • An anti-obesity drug screening method comprising the following steps (1) to (3):
  • a preventive or therapeutic agent for fat increase and Z or weight gain characterized by comprising an adiponectin gene or adiponectin.
  • a preventive or therapeutic agent for increasing fat mass and Z or weight gain comprising the plasmid vector according to any one of the above first to fourth.
  • the first to fourth inventions are useful for the production of transgenic animals that express adiponectin at high concentrations, and as gene therapy drugs for diseases caused by adiponectin deficiency (obesity, diabetes, arteriosclerosis, etc.) Can be used.
  • the fifth invention is useful for preparing a transgenic animal that expresses a target gene at a high concentration in a liver-specific manner, and is useful as a gene therapy drug that expresses in a liver-specific manner.
  • Sixth force By the transgenic animal of the seventh invention, the physiological significance of adiponectin of the following 1) to 4) is clarified, and adiponectin or its agonist is effective for lifestyle-related diseases such as diabetes and hypertrophy. Can know the possibility of being a therapeutic drug
  • the eighth invention it becomes possible to screen for therapeutic agents for hyperadiponectinemia.
  • the ninth invention makes it possible to screen for anti-obesity drugs.
  • adiponectin can be surely expressed at a high concentration.
  • FIG. 1 is a graph showing blood adiponectin concentration (average) in a group of transgenic mice of the present invention. Wild represents a wild-type mouse, and Linel represents a transgenic mouse (Tg mouse).
  • FIG. 2 is a graph showing the state of weight gain (average) when a high-calorie diet is administered to the transgenic mouse (Tg mouse) (male) group of the present invention.
  • FIG. 3 is a graph showing the increase in body weight when the (male) group and normal food are administered to the transgenic mice (Tg mice) of the present invention.
  • FIG. 4 is a graph showing the state of weight gain (average) when a high-calorie diet was administered to the transgenic mouse (Tg mouse) (female) group of the present invention.
  • FIG. 5 is a diagram showing the state of weight gain (average) when normal food is administered to the group of transgenic mice (Tg mice) (female) of the present invention.
  • FIG. 6 is a view showing the blood fat (neutral fat, cholesterol) reducing effect of the transgenic mouse (Tg mouse) (male) of the present invention under normal feeding.
  • FIG. 7 is a graph showing the visceral fat and subcutaneous fat reducing effects of the transgenic mouse (Tg mouse) (male) of the present invention under a high calorie high sucrose diet.
  • FIG. 8 is a graph showing the life prolonging effect of the transgenic mouse (Tg mouse) (male) of the present invention under a high calorie high sucrose diet.
  • FIG. 9 A diagram showing the size of subcutaneous adipocytes of wild-type mice under a high-calorie high-sucrose diet (HE staining, 100 times).
  • FIG. 10 is a view showing the size of subcutaneous adipocytes of a transgenic mouse (Tg mouse) of the present invention under a high calorie high sucrose diet (HE staining, 100 times).
  • FIG. 11 A diagram showing the visceral fat cell size of wild-type mice under a high-calorie high-sucrose diet (HE staining, 100 times).
  • FIG. 12 is a view showing the visceral fat cell size of a transgenic mouse (Tg mouse) of the present invention under a high-calorie high-sucrose diet (HE staining, 100 times).
  • FIG. 13 is a diagram showing the size of subcutaneous adipocytes of wild-type mice under normal diet (HE staining, 100 times).
  • FIG. 14 is a view showing the size of subcutaneous fat cells of a transgenic mouse (Tg mouse) of the present invention under normal diet (HE staining, 100 times).
  • FIG. 15 is a diagram showing the visceral fat cell size of wild-type mice under normal diet (HE staining, 100 times).
  • FIG. 16 is a view showing the visceral fat cell size of the transgenic mouse (Tg mouse) of the present invention under normal diet (HE staining, 100 times).
  • adiponectin is a substance that exists in a large amount in the blood of normal animals. Human adiponectin is expressed by a known human adiponectin gene described later.
  • the adiponectin used in the present invention includes proteins extracted from yeast and Escherichia coli by genetic recombination, proteins produced by chemical synthesis, and the like in addition to natural extracted proteins from animals including humans.
  • the adiponectin used in the present invention includes a variant in which a part of the amino acid sequence is deleted, substituted or added as long as it has a function substantially equivalent to that of adiponectin.
  • the function substantially equivalent to adiponectin refers to a function capable of preventing obesity, diabetes, arteriosclerosis and the like by gene administration or administration as an expressed polypeptide to adiponectin gene-deficient mice of Patent Document 1, for example.
  • adiponectin gene referred to in the present invention, as long as the expressed protein can express a protein having substantially the same function as the above-mentioned adiponectin, a part of the gene sequence is deleted or other Also included are those that have been replaced by bases or have other base sequences added to the structural gene or at the 5, 5 or 3, end.
  • the human adiponectin gene sequence is represented by, for example, NCBI ACCESSION No. D45371.
  • genes can also be synthesized based on cDNA produced from human adiponectin mRNA using reverse transcriptase or the like.
  • the transgenic animal when producing a transgenic animal, in order to make the gene expression more reliable and confirm its in vivo effect, it is derived from the same animal as the transgenic animal. It is preferred to use the adiponectin or adiponectin gene. On the other hand, when selecting an adiponectin gene derived from a species different from that of the animal to be introduced, it is preferable in that the behavior of the adiponectin can be searched by distinguishing from the adiponectin originally possessed by the target animal.
  • adiponectin or adiponectin gene is used as the medicament of the present invention, it is derived from humans, and it is produced by genetic recombination in Escherichia coli and yeast, and a synthetic protein consisting of the same or similar sequence. This is preferable because it has less influence on the living body and can surely exert the original function of adiponectin.
  • adiponectin or adiponectin gene is used as the medicament of the present invention, it is derived from humans, and it is produced by genetic recombination in Escherichia coli and yeast, and a synthetic protein consisting of the same or similar sequence. This is preferable because it has less influence on the living body and can surely exert the original function of adiponectin.
  • the plasmid vector of the present invention contains a liver-specific expression promoter and adiponectin gene as its constituent elements.
  • liver-specific expression promoters include promoters derived from genes of proteins specifically produced in the liver, such as the SAP promoter (Iwanaga T, et al. Liver—specinc and high-level expression of human serum amyloid P component gene in transgenic mice. Dev Genet. 1989; 10 (5): 365-71.).
  • the plasmid used in the plasmid vector of the present invention is not particularly limited. For example, those having a large gene expression level in eukaryotes are preferred. It preferably contains a poly A sequence that is useful for fishing. Specific examples include pSG5 plasmid vector (Stratagene). In addition, it is preferable to use a part of this pSG5 also in the plasmid vector of the fifth invention other than the first to fourth cases.
  • the plasmid vector of the present invention can be produced according to a conventional method (Current Protocols in Molecular Biology Frederick M. Ausubel (Author) (1988/11/14) John Wiley & Sons Inc).
  • the plasmid vector of the present invention can be used for production of a transgenic animal as a disease state model.
  • plasmid vectors of the present invention include those containing a gene of the target protein instead of the adiponectin gene. This plasmid vector can efficiently express the target protein in the liver.
  • mice As animals used in the present invention, rodents are preferred, such as mice, rats, Forces such as Muster Among others, C57BL / 6N mice (B6 mice), Balb / c mice and the like are preferably used, and C57BL / 6N mice are particularly preferable.
  • B6 mice C57BL / 6N mice
  • Balb / c mice and the like are preferably used, and C57BL / 6N mice are particularly preferable.
  • the introduction rodent is a mouse as an example.
  • the present invention is not limited to the mouse.
  • the transgenic animal of the present invention can be produced, for example, by transplanting an embryo obtained by the following method to a borrowed animal.
  • methods that are generally used for gene transfer are not limited to these methods.
  • a gene fragment such as a plasmid vector containing a specific promoter and adiponectin gene obtained as described above is injected into a pronuclear embryo of a mouse fertilized egg by, for example, microphone injection or the like. Confirmation of the recombinant gene injection can be confirmed by PCR using a DNAesay kit [Qiagen, Germ any] extracted from tissues such as the tail of a generated mouse (Funda).
  • transgenic animal that stably expresses the adiponectin gene. Therefore, the above-mentioned animal is founded as a founder and crossed with a wild-type mouse. It is preferable to select those that highly express adiponectin.
  • Examples of screening methods include PCR analysis using tail genomic DNA, ELISA analysis of adiponectin in serum, and Western blotting analysis of adiponectin in liver tissue.
  • the amount of the gene fragment containing the promoter and the adiponectin gene can be appropriately adjusted according to the degree of the desired disease, etc., and is not particularly limited.
  • the transgenic animal of the present invention can be used to verify the role of adiponectin in obesity, diabetes, etc., in addition to the angular force different from that of adiponectin-deficient mice. It can also be used for screening of drugs such as anti-obesity drugs. ⁇ Screening method for therapeutic agent for hyperadiponectinemia of the present invention>
  • the screening method of the present invention can be carried out by ELISA analysis of adiponectin in serum, Western blotting analysis of adiponectin in liver tissue before and after administration of a test substance.
  • the screening method for a therapeutic agent for hyperadiponectinemia is to prevent and improve anorexia nervosa. 'Therapeutic agent screening methods are also included.
  • the antiobesity drug screening method of the present invention can be carried out, for example, as follows.
  • First stage The gene expression state of a transgenic animal of the present invention that expresses adiponectin at a high concentration and a wild type that shows a general expression level of adiponectin are compared.
  • Second stage Based on the results of the analysis, a substance that exhibits a certain behavior due to the expression of adiponectin is selected. Substances that exhibit a certain behavior include substances that have been newly expressed in the body, substances that have increased in expression, substances that have decreased in expression, and substances that have disappeared. Third stage: Select one of the following (i) to (iv) as an anti-obesity drug.
  • normal diet may be used.
  • high calorie and Z or high sucrose diet the gene expression state between wild type and transgenic animals This is preferable because the difference is considered to be clear.
  • wild type and trance are more likely to be fed with high-calorie and Z- or high-sugar diets than with normal diets. This is apparent from the remarkable difference in the size of fat cells from that of the animal.
  • a high-calorie diet is one that contains more fat than a normal diet. For example, a fat amount of 30% by weight or more is preferred, and more preferably 40% by weight or more. Specific examples include high-calorie diets for breeding mice (7.5% carbohydrate, 24.5% protein, 60% fat, oriental yeast KK, F2HFD2).
  • a high sucrose diet is one that contains more sugar than a normal diet, but when used in the first stage, the higher the sugar ratio, the easier it is to obtain a difference from the regular diet in comparative experiments. Therefore, for example, the sucrose content is preferably 15% by weight or more, more preferably 20% by weight or more.
  • “(i) substance capable of controlling in vivo expression” means that (i) is newly increased in expression or expression level due to adiponectin!]
  • “(i) substance capable of controlling in vivo expression” is a substance that promotes the expression of (i).
  • (i) substance capable of controlling in vivo expression is a substance that suppresses the expression of (i).
  • a substance having structural or functional commonality with (i) or (ii) means, for example, (i) or (ii) a force protein Examples include a protein having the same enzyme activity as the protein, and a substance having the same basic skeleton when (ii) is a low molecular weight compound.
  • the effect of the selected substance is, for example, administered to a wild-type animal or an animal with adiponectin deficiency, followed by administration of high calorie and Z or high sucrose diet, and the body weight is measured over time.
  • the effect as an anti-obesity drug can be confirmed.
  • the target animal can be distinguished from the original adiponectin and searched. .
  • this screening method also confirms the prophylactic or therapeutic effect of a test substance in addition to the so-called primary screening for selecting a desired prophylactic or therapeutic agent from a plurality of candidates.
  • a secondary screening confirmation test is included to confirm.
  • Adiponectin or a gene thereof can be used as a preventive or therapeutic agent for fat mass increase and Z or weight gain. Among them, it is useful as a preventive or therapeutic agent for fat mass increase and Z or weight gain caused by high calorie and Z or high sucrose diet.
  • the increase in fat mass includes an increase in the number of fat cells in addition to an increase in the size of fat cells.
  • the pharmaceutical (prophylactic or therapeutic agent) of the present invention may contain other ingredients as long as the effect thereof is not inhibited.
  • it is pharmaceutically acceptable.
  • excipients include organic excipients and inorganic excipients.
  • the active ingredient used in the medicament (preventive or therapeutic agent) of the present invention is a gene for adiponectin, it can be used as a solvent such as water and other injections as long as the effect is not inhibited. Commonly used components and the like can be included.
  • the medicament of the present invention may be combined with conventionally known medicaments of the same purpose.
  • intravenous administration such as intravenous injection, intramuscular administration, transdermal administration, intradermal administration, subcutaneous administration, abdominal administration Intracavitary administration, rectal administration, mucosal administration, inhalation, etc. may be mentioned, but intravenous administration such as intravenous injection is preferable in terms of maintaining a constant blood clot concentration.
  • dosage forms for oral administration include forms such as tablets, capsules, granules, powders, pills, troches, or syrups.
  • the content of the active ingredient in the preparation of adiponectin used as the medicament of the present invention varies depending on the dosage form, cannot be generally limited, and is within the range where various dosage forms are possible.
  • a liquid preparation 0.0001 to 10 (wZv%), preferably ⁇ 0.001 to 5 (wZv%), particularly in the case of an injection, 0.0002 to 0. 2 (w / v%), preferably 0.001 to 0.1 (w / v%), 0.01 to 50 (wZw%) for solid agents, preferred
  • the force that can be prepared as 0.02 to 20 (wZw%) or the like is not necessarily limited to this range.
  • the dosage of the medicament of the present invention varies depending on the route of administration, symptoms, age, body weight, form of the preventive or therapeutic agent, etc.
  • a subject who needs to treat the active ingredient (adiponectin) in the medicament 0.005 to 500 mg per kg body weight, preferably 0.1 to: LOOmg, but for adults, the lower limit is 0. Olmg (preferably 0.1 mg), the upper limit is 20 g (preferably 2000 mg , More preferably 500 mg, and even more preferably lOO mg), and it is desirable to administer in one or several divided doses according to the symptoms.
  • DNA, RNA, plasmid, virus vector, etc. can be used as a gene form when the gene encoding adiponectin is used as a drug in gene therapy. It may be a real chain. Thus, even when used as a drug in gene therapy, a modified pSG5 plasmid containing a SAP promoter, a rabbit j8 globulin intron, a poly A sequence, etc. as used in the preparation of the above-described transgenic animal. Vectors are preferred.
  • a method of directly administering an expression plasmid into a muscle (DNA vaccine method), a ribosome method, a lipofectin method, a microinjection method, a calcium phosphate method, an electopore position method, etc.
  • the ribosome method is preferred.
  • virus vectors When viral vectors are used (Nikkei Science, April 1994, 20-45, Monthly Pharmaceutical Affairs, 36 (1), 23-48 (1994), Experimental Medicine Extra Number, 12 (15), (1994 ), And references cited therein), etc., can be carried out by incorporating the gene of interest into the virus.
  • the virus used for the virus vector include retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, box virus, poliovirus, simbis virus and other DNA viruses or RNA viruses.
  • retroviruses, adenoviruses, adeno-associated viruses, vaccinia viruses and the like are preferred, and adenoviruses are particularly preferred.
  • an appropriate route of administration can be selected according to the disease or symptom to be treated.
  • Examples of the administration route include vein, artery, subcutaneous, intradermal, intramuscular and the like.
  • the "in vivo method” When administered by the "in vivo method", for example, it can be in the form of a preparation such as a liquid. In general, it is possible to add various components that are commonly used in injections and the like as required by the form of injections containing genes.
  • a ribosome or membrane fusion ribosome containing a gene can be used as a form of a ribosome preparation such as a suspension, a freezing agent, or a centrifugal concentrated freezing agent.
  • a ribosome preparation such as a suspension, a freezing agent, or a centrifugal concentrated freezing agent.
  • the content of the gene in the preparation can be appropriately adjusted depending on the disease to be treated, target organ, patient age, body weight, etc.
  • the normal gene is 0. OOOlmg ⁇ : L00mg, preferably 0.001mg ⁇ lOmg, and it is appropriate to administer this once every several days to several months.
  • a vector containing SAP-promoter rabbit j8-globulin intron-human adiponectin cDNA-polyadenylation signal was constructed.
  • pSG5 vector (Stratagene), which is an expression vector with early SV40 promoter ⁇ —— rabbit 13-globulin intron polyadenylation signal. Transfer pSG5 vector to SCSI 10 cell The pSG5 vector was increased with the Qiagen plasmid kit.
  • the SAP promoter was used to selectively express adiponectin in the liver. Based on reports of overexpression of leptin and BNP in the liver using this promoter, PCR was performed by amplifying -677 bp to -9 bp upstream of the human SAP gene and adding Sal 1 and Cla 1 cleavage sites at both ends. The product was incorporated into the TA easy vector. By digesting this integrated TA easy vector with Sal 1 and Cla 1 restriction enzymes and ligating the excised PCR product to the Sal 1 and Cla 1 sites of the pSG5 vector, the early SV40 promoter in the pSG5 vector is obtained. Replaced with SAP promoter.
  • an expression vector (hSAP_pSG5) containing a human SAP promoter rabbit j8-globulin intron-polyadenylation signal that can be expressed specifically in the liver was constructed.
  • a cDNA library of mouse adipose tissue primers were prepared to create BamHl and EcoRl sites at both ends, and the full length of human adiponectin cDNA was amplified by PCR.
  • a PCR product with BamHl and EcoRl cleavage sites at both ends was incorporated into the TA easy vector.
  • This integrated TA eas y vector was digested with BamHl and EcoRl restriction enzymes, and the excised product was ligated between BamHl and EcoRl present in the cloning site of the hSAP-pSG5 expression vector.
  • a vector containing a human SAP promoter, one rabbit ⁇ globulin intron, human adiponectin cDNA polyadenylation signal was constructed.
  • the vector prepared above was cleaved with Sal 1, the vector-derived sequence was removed by agarose gel electrophoresis, and the DNA fragment (about 2 kb) was purified by Gene Clean II kit.
  • a transgenic mouse was prepared according to a conventional method. As the mouse, C57BL / 6N mouse was used.
  • the amount of adiponectin in one group was 5 to 10 times the normal amount.
  • the blood concentration shown in Fig. 1 is the average value of each group (8 animals in each group).
  • a group showing 3 to 5 times the adiponectin concentration was also obtained. That is, in the method for producing a transgenic animal of the present invention, various adiponectin genesis are generated. Transgenic animals with current capabilities can be obtained.
  • mice Since these transgenic mice express a high concentration of adiponectin immediately after birth, they are suitable for investigating the effects of hyperadiponectinemia over a long period of time.
  • this adiponectin is expressed specifically in the liver and is suitable for examining the direct influence of adiponectin on the liver.
  • human adiponectin since human adiponectin is expressed, its function can be evaluated in distinction from mouse-derived adiponectin.
  • mice and wild type mice 80 g of high calorie diet for breeding mice (7.5% carbohydrate, 24.5% protein, 60% fat, Oriental yeast KK, F2HFD2) was mixed with 20 g of sucrose. I started to give it a high-calorie diet or (2) a regular diet from the 8th week of life. Each group had 8 animals. The same experiment was conducted for both males and females.
  • wild type mice showed a significant weight gain
  • the transgenic mice of the present invention fed a high-calorie diet until 15 weeks of age. Nevertheless, he gained power without any weight gain.
  • the transgenic animal of the present invention is useful for elucidating the mechanism for preventing and improving obesity of adiponectin under the administration of a high-calorie diet.
  • the plasmid vector of the present invention is also useful for treatment of adiponectin deficiency, obesity 'diabetes' prevention of arteriosclerosis' and the like.
  • the normal diet started to be applied after weaning when it became available. Each group had 8 animals. In each group, the experiment was conducted with males.
  • Fig. 6 shows the results of measurement of blood fat (neutral fat and cholesterol) after breeding these mice up to 20 weeks of age.
  • Tg mice were low in lipids in blood compared with wild-type mice under normal diet.
  • this Tg mouse or adiponectin and developing its agonist it can be a therapeutic agent for hyperlipidemia
  • a high-calorie high-sucrose diet of the same kind as in Example 1 was started to be given to each group of transgenic mice and wild-type mice prepared as in Example 1 from the 8th week after birth. There were 6 animals in each group. In each group, the experiment was conducted with males.
  • Fig. 7 shows the results of measurement of visceral fat and subcutaneous fat after these mice were raised to 20 weeks of age after birth.
  • Tg mice were not only those with visceral fat mass but also those with low subcutaneous fat mass compared to wild-type mice under the high calorie high sugar diet.
  • this Tg mouse or adiponectin By investigating the mechanism of action of this Tg mouse or adiponectin and developing its drug, it may be a therapeutic drug that reduces fat mass and improves metabolic syndrome (metabolic syndrome).
  • Example 4 (Confirmation of life-prolonging effect of adiponectin under high calorie and Z or high sucrose diet)
  • a high-calorie high-sucrose diet of the same kind as in Example 1 was started to be given to each group of transgenic mice and wild-type mice prepared as in Example 1 from the 8th week after birth. There were 12 animals in each group. In each group, the experiment was conducted with males.
  • Fig. 8 shows the results of measuring the lifespan of these mice.
  • Each group of transgenic mice and wild type mice prepared as in Example 1 began to receive a high calorie high sucrose diet from the 8th week of life. There were 6 animals in each group. In each group, the experiment was conducted with males.
  • mice were raised to 20 weeks of age, subcutaneous adipose tissue of the whole mouse was collected under ether anesthesia. After measuring the weight, a part of it was fixed in formalin. The results of observing the size of subcutaneous fat are shown in FIGS. 9 and 10 (100-fold HE staining).
  • visceral adipose tissue present in the upper part of the mouse accessory testicle, around the kidney, and around the intestine was collected under ether anesthesia. After measuring the weight, a part of it was fixed in formalin. The result of observing the size of visceral fat Shown in Figures 11 and 12 (100x HE staining).
  • the fat cell size in the visceral adipose tissue is clearly higher in the # 11 Tg mouse than in the wild mouse under the high calorie high sugar diet feeding condition. small.
  • adipocytes in subcutaneous adipose tissue is comparable to that of wild mice under the conditions of normal feeding.
  • visceral fat of the mice bred in (3) In order to observe the visceral fat of the mice bred in (3), visceral adipose tissue present in the upper part of the mouse accessory testicle, around the kidney, and around the intestine was collected under ether anesthesia. After measuring the weight, a part of it was fixed in formalin.
  • adipocytes in visceral fat thread and tissue is comparable or slightly higher in the # 11 Tg mice than in the wild mice under normal feeding conditions. small.
  • a vector containing the adiponectin gene of the present invention can be used to produce a disease model animal.
  • Transgenic animals using this vector are also adiponectin It is useful for examining the role of obesity in obesity, and is useful for screening for a therapeutic agent for hyperadiponectinemia, a preventive agent for anorexia nervosa, and an anti-obesity agent.
  • the plasmid vector of the present invention is a vector capable of producing a large amount of the target product in the liver.
  • the pharmaceutical of this invention can prevent the increase in the amount of fat resulting from high calories and Z or high sucrose, etc., and can prevent or treat weight gain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention vise à préparer une souris ne souffrant pas d'obésité même si on la nourrit avec une nourriture riche en calories et concerne un vecteur capable de permettre la surexpression de l'adiponectine dans le foie, un animal transgénique obtenu en utilisant ce vecteur, un procédé de recherche par criblage d'un remède pour l'adiponectinémie, un agent préventif ou un remède contre une augmentation de la masse adipeuse et/ou une prise de poids et ainsi de suite. L'invention concerne un plasmide vecteur contenant un promoteur de composant amyloïde P sérique (SAP) humain et un gène de l'adiponectine ; une souris transgénique ayant celui-ci transféré en elle ; un procédé de recherche par criblage utilisant celui-ci ; et un agent préventif ou un remède contre une augmentation de la masse adipeuse et/ou une prise de poids lequel contient un gène de l'adiponectine ou de l'adiponectine.
PCT/JP2005/013667 2004-07-27 2005-07-26 Plasmide vecteur, animal transgénique, procédé de recherche par criblage d'un médicament et médicament WO2006011491A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-219279 2004-07-27
JP2004219279 2004-07-27

Publications (1)

Publication Number Publication Date
WO2006011491A1 true WO2006011491A1 (fr) 2006-02-02

Family

ID=35786242

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/013667 WO2006011491A1 (fr) 2004-07-27 2005-07-26 Plasmide vecteur, animal transgénique, procédé de recherche par criblage d'un médicament et médicament

Country Status (1)

Country Link
WO (1) WO2006011491A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011051912A (ja) * 2009-08-31 2011-03-17 Kagome Co Ltd レプチン産生促進剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003339272A (ja) * 2002-05-24 2003-12-02 Japan Science & Technology Corp アディポネクチン遺伝子欠損非ヒト動物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003339272A (ja) * 2002-05-24 2003-12-02 Japan Science & Technology Corp アディポネクチン遺伝子欠損非ヒト動物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COMBS TP ET AL: "A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity.", ENDOCRINOLOGY., vol. 145, no. 1, January 2004 (2004-01-01), pages 367 - 383, XP002993025 *
KADOWAKI T AND YAMAUCHI T ET AL: "Adiponectin and adiponectin receptors.", ENDOCRIN REV., vol. 26, no. 3, May 2005 (2005-05-01), pages 439 - 451, XP002993027 *
OANA F. ET AL: "Adiponectin receptor 2 expression in liver and insulin resistance in db/db mice given a beta3-adrenoceptor agonist.", EUR J PHARMACOL., vol. 518, no. 1, 25 July 2005 (2005-07-25), pages 71 - 76, XP004981535 *
SATO H ET AL: "Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats.", DIABETES., vol. 54, no. 5, May 2005 (2005-05-01), pages 1304 - 1313, XP002993026 *
YAMAUCHI T ET AL: "Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis.", J BIOL CHEM., vol. 278, no. 4, 24 January 2003 (2003-01-24), pages 2461 - 2468, XP002993024 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011051912A (ja) * 2009-08-31 2011-03-17 Kagome Co Ltd レプチン産生促進剤

Similar Documents

Publication Publication Date Title
Pedroso et al. Inactivation of SOCS3 in leptin receptor-expressing cells protects mice from diet-induced insulin resistance but does not prevent obesity
Levin et al. Decreased food intake does not completely account for adiposity reduction after ob protein infusion.
He et al. Insulin expression in livers of diabetic mice mediated by hydrodynamics-based administration
US7745691B2 (en) Genetically modified mouse lacking diacylglycerol acyltransferase-1 (DGAT-1) activity
Gupta et al. Disrupting the ghrelin-growth hormone axis limits ghrelin's orexigenic but not glucoregulatory actions
CN108004310B (zh) 肾素(原)受体(p)rr基因及其抑制剂的应用
Ramasubramanian et al. Are TallyHo Mice A True Mouse Model for Type 2 Diabetes and Alzheimer’s Disease?
US6703215B2 (en) Inhibitors of the inositol polyphosphate 5-phosphatase SHIP2 molecule
US20150361146A1 (en) MG53 Mutant, Methods of Mutation and Use Thereof
CA2493859C (fr) Medicament preventif/curatif pour l'arteriosclerose comprenant de l'adiponectine
WO2008032450A1 (fr) Agent prophylactique et/ou thérapeutique pour une stéatose hépatique
WO2006011491A1 (fr) Plasmide vecteur, animal transgénique, procédé de recherche par criblage d'un médicament et médicament
JPWO2005097171A1 (ja) 抗肥満薬
Tenta et al. Roles of transmembrane protein 97 (TMEM97) in adipose tissue and skeletal muscle
Grasa et al. Oleoyl-estrone lowers the body weight of both ob/ob and db/db mice
US20050096264A1 (en) Methods for treating obesity and related conditions with glycoprotein hormone beta family hormones
Ortiz Characterization and Lifespan Assessment of Inducible Growth Hormone Receptor Disrupted Mice at Six Months of Age
Ramos-Lobo et al. João AB Pedroso1, Daniella C. Buonfiglio1, Lais I. Cardinali1, Isadora C. Furigo1, Angela M.
Cohen Leptin and the control of body weight and metabolism: Role for stearoyl CoA desaturase-1 and other leptin-regulated genes in the liver
JP2003304778A (ja) トランスジェニック非ヒト哺乳動物
Lewis The role of VGF and its derived peptides in the regulation of energy homeostasis
MAHMOUDI et al. The demonstration of polyethylenimine mediated gene transfer into the rodent hypothalamus results in persistent over-expression and phenotypic change
JP2015107950A (ja) 成長ホルモン発現抑制剤、成人成長ホルモン分泌不全症モデル非ヒト動物、成人成長ホルモン分泌不全症モデル非ヒト動物の作製方法、褐色脂肪細胞の機能調整剤、脂肪蓄積症モデル非ヒト動物及び脂肪蓄積症モデル非ヒト動物の作製方法
Fehlings Physiological and morphological characterization of trangenic pigs expressing a dominant-negative glucose-dependent insulinotropic polypeptide receptor (GIPRdn)
WO2017214383A1 (fr) Utilisation de la protéine 1 liée à c1q/tnf (trecp1) pour le traitement de la stéatose hépatique.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP